Among the different drug development strategies, many hybrid molecules have been explored by combining in the same molecular entity approved anti-AD drugs, or their determinant pharmacophores, with other biologically active molecular moieties to enable the hitting of other important AD targets, such as amyloid beta (Aβ) aggregates, radical oxygen species (ROS), redox-active metal ions and enzymes (e.g., monoamine oxidase, beta-secretase 1) [8,9,10,11,12,13]. The gene discussed is BACE1; the disease is Alzheimer disease.